欧洲和亚洲使用抗胸腺细胞球蛋白一线治疗再生障碍性贫血:2001-2012年955例患者结局
该研究评估了955例再生障碍性贫血患者接受兔抗胸腺细胞球蛋白(Thymoglobulin)联合环孢素一线治疗的结局。2001-2008年与2009-2012年两个时间段90天内死亡率分别为5.7%和2.4%(P=0.007)。全组10年生存率为70%,无移植生存率为64%。6个月有反应者生存率87%,无反应者为61%(P<0.0001)。
要点
- 2009-2012年90天内死亡率为2.4%,低于2001-2008年的5.7%(P=0.007)。
- 6个月有反应者10年生存率为87%,无反应者为61%(P<0.0001)。
- 多因素分析中,疾病严重程度、年龄及诊断至治疗间隔是生存的预测因素。
核心结论
- Thymoglobulin一线治疗再生障碍性贫血早期死亡率低,且2008年后进一步降低;患者年龄、诊断至治疗间隔及疾病严重程度仍是反应和生存的强预测因素。
研究设计与样本
- 研究纳入955例再生障碍性贫血患者,2001-2008年治疗492例,2009-2012年治疗463例,均接受Thymoglobulin一线治疗;中位年龄21岁(范围1-84岁)。
主要发现
- 两个时间段90天内死亡率分别为5.7%和2.4%(P=0.007)。
- 全组10年生存率为70%,无移植生存率为64%。
- 6个月有反应者10年生存率为87%,无反应者为61%(P<0.0001)。
- 6个月无反应者中,后续接受移植者(n=110)10年生存率为64%,未接受移植者(n=266)为60%(P=0.1)。
- 累积反应率在90天、180天和365天分别为37%、52%和65%。
关键数值与推荐
- 多因素分析中生存的预测因素包括疾病严重程度、患者年龄及诊断至治疗间隔。
- 6个月反应的多因素分析中,负面预测因素包括年龄较大、诊断至治疗间隔较长及疾病严重程度较高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim of this study was to assess the outcome of patients with aplastic anemia (AA), receiving rabbit anti-thymocyte globulin (Thymoglobulin, SANOFI) and cyclosporin, as first line treatment. Eligible were 955 patients with AA, treated first line with Thymoglobulin, between 2001 and 2008 (n = 492), or between 2009 and 2012 (n = 463). The median age of the patients was 21 years (range 1-84). Mortality within 90 days was 5.7% and 2.4%, respectively in the two time periods (P = .007).The actuarial 10-year survival for the entire population was 70%; transplant free survival was 64%. Predictors of survival in multivariate analysis, were severity of the disease, patients age and the interval between diagnosis and treatment. Survival was 87% vs 61% for responders at 6 months versus nonresponders (P < .0001). The 10-year survival of nonresponders at 6 months, undergoing a subsequent transplant (n = 110), was 64%, vs 60% for patient not transplantated (n = 266) (P = .1). The cumulative incidence of response was 37%, 52%, 65% respectively, at 90, 180, and 365 days. In multivariate analysis, negative predictors of response at 6 months, were older age, longer interval diagnosis treatment, and greater severity of the disease. In conclusion, early mortality is low after first line treatment of AA with Thymoglobulin, and has been further reduced after year 2008. Patients age, together with interval diagnosis-treament and severity of the disease, remain strong predictors of response and survival.
引用
- Bacigalupo A, Oneto R, Schrezenmeier H, et al. First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012. Am J Hematol. 2018. PMID: 29498107. doi:10.1002/ajh.25081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。